Inflammation profile, cell cycle arrest, cell growth arrest, and ROS production implied that treated CML CD34+ cells might undergo senescence and lose their self-renewal capability. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.